However, it was interesting in our previous study that the initial dosage recommendation for sirolimus in children with TSC, CYP3A4, and CYP3A5 polymorphism did not significantly affect sirolimus clearance rates (Wang et al., 2020). Here, CYP3A4 is linked to tuberous sclerosis.